{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:27:26Z","timestamp":1793946446368,"version":"4.8.0"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.critrevonc.2026.105506","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:28:35Z","timestamp":1785281315000},"page":"105506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["RET alterations in thyroid cancer: Molecular mechanisms, targeted therapies, and emerging resistance"],"prefix":"10.1016","volume":"226","author":[{"given":"Shujing","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanfen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangtong","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Tong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105506_bib1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/MMBR.67.4.657-685.2003","article-title":"RNA interference: biology, mechanism, and applications","volume":"67","author":"Agrawal","year":"2003","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.critrevonc.2026.105506_bib2","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1186\/s12885-024-13345-9","article-title":"A novel role for nonactin: interfering with G-quadruplex in RET-driven medullary thyroid cancer","volume":"24","author":"Alqahtani","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105506_bib3","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/PO.20.00096","article-title":"Systemic and CNS activity of selective RET inhibition with selpercatinib (LOXO-292) in a patient with RET-mutant medullary thyroid cancer with extensive CNS metastases","author":"Andreev-Drakhlin","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib4","unstructured":"Applied Pharmaceutical Science, Inc., 2026. A phase 1\/1b study to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of APS03118 in adult patients with unresectable locally advanced or metastatic solid tumors harboring RET mutations or fusions (Clinical trial registration No. NCT05653869). clinicaltrials.gov."},{"key":"10.1016\/j.critrevonc.2026.105506_bib5","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1055\/a-1089-7870","article-title":"Updates on the management of thyroid cancer","volume":"52","author":"Araque","year":"2020","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.critrevonc.2026.105506_bib6","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cytogfr.2005.05.010","article-title":"RET tyrosine kinase signaling in development and cancer","volume":"16","author":"Arighi","year":"2005","journal-title":"Cytokine & Growth Factor. Rev."},{"key":"10.1016\/j.critrevonc.2026.105506_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.annonc.2020.11.021","article-title":"ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research","volume":"32","author":"Belli","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib8","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1089\/thy.2013.0137","article-title":"vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer","volume":"23","author":"Bentzien","year":"2013","journal-title":"Thyroid"},{"key":"10.1016\/j.critrevonc.2026.105506_bib9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/jama.2023.26348","article-title":"Thyroid Cancer: A Review","volume":"331","author":"Boucai","year":"2024","journal-title":"Jama"},{"key":"10.1016\/j.critrevonc.2026.105506_bib10","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/sj.onc.1200206","article-title":"High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation","volume":"15","author":"Bounacer","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105506_bib11","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-23-0354","article-title":"Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy","volume":"31","author":"Brose","year":"2024","journal-title":"Endocr. -Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105506_bib12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105506_bib13","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-23-0117","article-title":"RET fusion genes in pediatric and adult thyroid carcinomas: cohort characteristics and prognosis","volume":"30","author":"Bulanova Pekova","year":"2023","journal-title":"Endocr. -Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105506_bib14","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1089\/thy.2022.0027","article-title":"A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer","volume":"32","author":"Capdevila","year":"2022","journal-title":"Thyroid"},{"key":"10.1016\/j.critrevonc.2026.105506_bib15","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1038\/sj.onc.1207810","article-title":"Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors","volume":"23","author":"Carlomagno","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105506_bib16","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1038\/s41379-020-0638-5","article-title":"Clinicopathologic features of kinase fusion-related thyroid carcinomas: An integrative analysis with molecular characterization","volume":"33","author":"Chu","year":"2020","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib17","article-title":"Mechanisms of resistance to RET-directed therapies","volume":"32","author":"Clifton-Bligh","year":"2024","journal-title":"Endocr. -Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105506_bib18","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1210\/jc.2017-01039","article-title":"Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma","volume":"102","author":"Cote","year":"2017","journal-title":"J. Clin. Endocrinol. & Metab."},{"key":"10.1016\/j.critrevonc.2026.105506_bib19","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1210\/er.2006-0017","article-title":"RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors","volume":"27","author":"De Groot","year":"2006","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.critrevonc.2026.105506_bib20","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1210\/clinem\/dgae283","article-title":"Clinical Activity of Selpercatinib in RET -mutant Pheochromocytoma","volume":"110","author":"Deschler-Baier","year":"2025","journal-title":"J. Clin. Endocrinol. & Metab."},{"key":"10.1016\/j.critrevonc.2026.105506_bib21","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.3390\/cancers15164146","article-title":"RET-Altered Cancers-A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity","volume":"15","author":"Desilets","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105506_bib22","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1089\/thy.2019.0477","article-title":"Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma","volume":"30","author":"Dias-Santagata","year":"2020","journal-title":"Thyroid"},{"key":"10.1016\/j.critrevonc.2026.105506_bib23","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-021-01063-9","article-title":"Therapeutic strategies in RET gene rearranged non-small cell lung cancer","volume":"14","author":"Drusbosky","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib24","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib25","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1177\/10507256251367352","article-title":"Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib\/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in RET -Mutant Medullary Thyroid Cancer","volume":"35","author":"Elisei","year":"2025","journal-title":"Thyroid\u00ae"},{"key":"10.1016\/j.critrevonc.2026.105506_bib26","unstructured":"FDA approves pralsetinib for RET-altered thyroid cancers FDA [WWW Document], 2020. URL https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pralsetinib-ret-altered-thyroid-cancers (accessed 6.11.25)."},{"key":"10.1016\/j.critrevonc.2026.105506_bib27","unstructured":"FDA approves selpercatinib for medullary thyroid cancer with a RET mutation FDA [WWW Document], 2024. URL https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-selpercatinib-medullary-thyroid-cancer-ret-mutation (accessed 6.10.25)."},{"key":"10.1016\/j.critrevonc.2026.105506_bib28","unstructured":"FDA approves selpercatinib for RET fusion-positive thyroid cancer FDA [WWW Document], 2024. URL https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-selpercatinib-ret-fusion-positive-thyroid-cancer (accessed 6.10.25)."},{"key":"10.1016\/j.critrevonc.2026.105506_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1414492","article-title":"The value of NGS-based multi-gene testing for differentiation of benign from malignant and risk stratification of thyroid nodules","volume":"14","author":"Fei","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neo.2017.10.010","article-title":"The GDNF Family: A Role in Cancer?","volume":"20","author":"Fielder","year":"2018","journal-title":"Neoplasia"},{"key":"10.1016\/j.critrevonc.2026.105506_bib31","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.mrrev.2012.09.002","article-title":"Medullary thyroid carcinoma (MTC) and RET proto-oncogene: Mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form","volume":"752","author":"Figlioli","year":"2013","journal-title":"Mutat. Res. \/Rev. Mutat. Res."},{"key":"10.1016\/j.critrevonc.2026.105506_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2022.101655","article-title":"Medullary thyroid cancer - An update","volume":"37","author":"Fugazzola","year":"2023","journal-title":"Best. Pract. & Res. Clin. Endocrinol. & Metab."},{"key":"10.1016\/j.critrevonc.2026.105506_bib33","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-24-0189","article-title":"Fluctuating obliterative bronchiolitis in RET-mutant medullary thyroid cancer patient treated with selpercatinib","volume":"13","author":"Gambale","year":"2024","journal-title":"Eur. Thyroid. J."},{"key":"10.1016\/j.critrevonc.2026.105506_bib34","unstructured":"Genentech Withdraws US Indication for Pralsetinib in Advanced or Metastatic RET+ Medullary Thyroid Cancer [WWW Document], 2023. OncLive. URL https:\/\/www.onclive.com\/view\/genentech-withdraws-us-indication-for-pralsetinib-in-advanced-or-metastatic-ret-medullary-thyroid-cancer (accessed 8.28.25)."},{"key":"10.1016\/j.critrevonc.2026.105506_bib35","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1210\/endrev\/bnad013","article-title":"Medullary Thyroid Cancer: Updates and Challenges","volume":"44","author":"Gild","year":"2023","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.critrevonc.2026.105506_bib36","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.3390\/molecules27248839","article-title":"Precious Gene: The Application of RET-Altered Inhibitors","volume":"27","author":"Gou","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.critrevonc.2026.105506_bib37","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.pop.2024.03.006","article-title":"Multiple Endocrine Neoplasia Type 1, Type 2A, and Type 2B","volume":"51","author":"Greenberg","year":"2024","journal-title":"Prim. Care Clin. Off. Pract."},{"key":"10.1016\/j.critrevonc.2026.105506_bib38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1507\/endocrj.K10E-260","article-title":"Prevalence of RET\/PTC rearrangement in benign and malignant thyroid nodules and its clinical application","volume":"58","author":"Guerra","year":"2011","journal-title":"Endocr. J."},{"key":"10.1016\/j.critrevonc.2026.105506_bib39","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00053","article-title":"Patterns of Treatment Failure After Selective Rearranged During Transfection (RET) Inhibitors in Patients With Metastatic Medullary Thyroid Carcinoma","author":"Hadoux","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib40","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid Cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105506_bib41","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/nmeth.2633","article-title":"Absolute quantification by droplet digital PCR versus analog real-time PCR","volume":"10","author":"Hindson","year":"2013","journal-title":"Nat. Methods"},{"key":"10.1016\/j.critrevonc.2026.105506_bib42","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.path.2019.08.004","article-title":"Treatment of Aggressive Thyroid Cancer","volume":"12","author":"Huang","year":"2019","journal-title":"Surg. Pathol. Clin."},{"key":"10.1016\/j.critrevonc.2026.105506_bib43","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1373\/clinchem.2014.221366","article-title":"Considerations for Digital PCR as an Accurate Molecular Diagnostic Tool","volume":"61","author":"Huggett","year":"2015","journal-title":"Clin. Chem."},{"key":"10.1016\/j.critrevonc.2026.105506_bib44","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1158\/1535-7163.MCT-21-0127","article-title":"The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G1 Cell-Cycle Arrest through c-Myc Downregulation","volume":"20","author":"Jiang","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105506_bib45","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s13023-019-1194-2","article-title":"Sequence characterization of RET in 117 Chinese Hirschsprung disease families identifies a large burden of de novo and parental mosaic mutations","volume":"14","author":"Jiang","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.critrevonc.2026.105506_bib46","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/jcph.2409","article-title":"Exposure-Response Relationships for Pralsetinib in Patients with RET-Altered Thyroid Cancer or RET Fusion-Positive Nonsmall Cell Lung Cancer","volume":"64","author":"Kassir","year":"2024","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib47","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00441-020-03262-1","article-title":"Intracellular RET signaling pathways activated by GDNF","volume":"382","author":"Kawai","year":"2020","journal-title":"Cell. Tissue Res."},{"key":"10.1016\/j.critrevonc.2026.105506_bib48","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1158\/1078-0432.CCR-21-0967","article-title":"FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions","volume":"27","author":"Kim","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105506_bib49","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1089\/thy.2020.0206","article-title":"Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer","volume":"31","author":"Koehler","year":"2021","journal-title":"Thyroid"},{"key":"10.1016\/j.critrevonc.2026.105506_bib50","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1349-7006.2009.01484.x","article-title":"Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis","volume":"101","author":"Koga","year":"2010","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105506_bib51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1530\/ERC-11-0155","article-title":"Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro","volume":"19","author":"Koh","year":"2012","journal-title":"Endocr. Relatl Cancer"},{"key":"10.1016\/j.critrevonc.2026.105506_bib52","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2021-1464","article-title":"Abstract 1464: Pre-clinical characterization of potent and selective next-generation RET inhibitors","volume":"81","author":"Kolakowski","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105506_bib53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1586\/17512433.2016.1102052","article-title":"Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer","volume":"9","author":"Krajewska","year":"2016","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib54","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1038\/s41467-020-15955-w","article-title":"Proteogenomics analysis unveils a TFG-RET gene fusion and druggable targets in papillary thyroid carcinomas","volume":"11","author":"Krishnan","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105506_bib55","doi-asserted-by":"crossref","first-page":"8807","DOI":"10.3390\/ijms21228807","article-title":"Currently Applied Molecular Assays for Identifying ESR1 Mutations in Patients with Advanced Breast Cancer","volume":"21","author":"Lee","year":"2020","journal-title":"IJMS"},{"key":"10.1016\/j.critrevonc.2026.105506_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101911","article-title":"RET fusions in solid tumors","volume":"81","author":"Li","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105506_bib57","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.annonc.2020.09.015","article-title":"Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer","volume":"31","author":"Lin","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib58","doi-asserted-by":"crossref","first-page":"e1129","DOI":"10.1210\/clinem\/dgaa913","article-title":"Pitfalls in RET Fusion Detection Using Break-Apart FISH Probes in Papillary Thyroid Carcinoma","volume":"106","author":"Liu","year":"2021","journal-title":"J. Clin. Endocrinol. & Metab."},{"key":"10.1016\/j.critrevonc.2026.105506_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2024.109549","article-title":"Dissection of RET p.M918T-driven progression of hereditary vs. sporadic medullary thyroid cancer","volume":"51","author":"Machens","year":"2025","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib60","article-title":"Insights into highly selective RET inhibitors in medullary thyroid cancer","volume":"35","author":"Matrone","year":"2024","journal-title":"Curr. Opin. Endocr. Metab. Res."},{"key":"10.1016\/j.critrevonc.2026.105506_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.864253","article-title":"Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine","volume":"13","author":"Matrone","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.critrevonc.2026.105506_bib62","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.annonc.2021.08.1987","article-title":"Significant response of medullary thyroid cancer choroidal metastases to highly selective RET inhibitor selpercatinib: a case report","volume":"32","author":"Matrone","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib63","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.beem.2017.06.001","article-title":"Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life","volume":"31","author":"Matrone","year":"2017","journal-title":"Best. Pract. & Res. Clin. Endocrinol. & Metab."},{"key":"10.1016\/j.critrevonc.2026.105506_bib64","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12022-024-09836-x","article-title":"Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management","volume":"35","author":"Mete","year":"2024","journal-title":"Endocr. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib65","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s43018-023-00630-y","article-title":"Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations","volume":"4","author":"Miyazaki","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105506_bib66","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cncy.21199","article-title":"Cytomorphological and molecular genetic findings in pediatric thyroid fine-needle aspiration","volume":"120","author":"Monaco","year":"2012","journal-title":"Cancer Cytopathol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib67","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.ejso.2018.11.009","article-title":"Detection of RET rearrangements in papillary thyroid carcinoma using RT-PCR and FISH techniques - A molecular and clinical analysis","volume":"45","author":"Musholt","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib68","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41467-018-02994-7","article-title":"A secondary RET mutation in the activation loop conferring resistance to vandetanib","volume":"9","author":"Nakaoku","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105506_bib69","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1385\/EP:13:1:03","article-title":"RET\/PTC rearrangement in thyroid tumors","volume":"13","author":"Nikiforov","year":"2002","journal-title":"Endocr. Pathol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105506_bib70","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/jnci\/djae250","article-title":"Prevalence of cancer survivors diagnosed during adolescence and young adulthood in the United States","volume":"117","author":"Page","year":"2025","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2026.105506_bib71","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00052","article-title":"D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms","author":"Porcelli","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib72","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/07435800.2024.2344103","article-title":"Sporadic and Familial Medullary Thyroid Carcinoma: A Retrospective Single Center Study on Presentation and Outcome","volume":"49","author":"Prinzi","year":"2024","journal-title":"Endocr. Res."},{"key":"10.1016\/j.critrevonc.2026.105506_bib73","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.jtho.2021.01.1619","article-title":"RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer","volume":"16","author":"Radonic","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib74","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s12020-020-02426-x","article-title":"Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer","volume":"71","author":"Ramos","year":"2021","journal-title":"Endocrine"},{"key":"10.1016\/j.critrevonc.2026.105506_bib75","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.3390\/cancers12113146","article-title":"Genetic Landscape of Papillary Thyroid Carcinoma and Nuclear Architecture: An Overview Comparing Pediatric and Adult Populations","volume":"12","author":"Rangel-Pozzo","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105506_bib76","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s10637-022-01259-x","article-title":"The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046","volume":"40","author":"Repetto","year":"2022","journal-title":"Invest. New. Drugs"},{"key":"10.1016\/j.critrevonc.2026.105506_bib77","unstructured":"Research, C. for D.E. and, 2024. FDA approves selpercatinib for RET fusion-positive thyroid cancer. FDA."},{"key":"10.1016\/j.critrevonc.2026.105506_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102372","article-title":"Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies","volume":"105","author":"Rom\u00e1n-Gil","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105506_bib79","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/1078-0432.CCR-20-2278","article-title":"Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion\u2013Positive Lung Cancer by Combining Selpercatinib with Crizotinib","volume":"27","author":"Rosen","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105506_bib80","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/s41467-022-28848-x","article-title":"The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers","volume":"13","author":"Rosen","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105506_bib81","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.critrevonc.2026.105506_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1474267","article-title":"The role of genetic and epigenetic modifications as potential biomarkers in the diagnosis and prognosis of thyroid cancer","volume":"14","author":"Sabi","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib83","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41574-021-00470-9","article-title":"The importance of the RET gene in thyroid cancer and therapeutic implications","volume":"17","author":"Salvatore","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib84","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1078-0432.CCR-15-1127","article-title":"A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer","volume":"22","author":"Schlumberger","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105506_bib85","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105506_bib86","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS3162","article-title":"A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer","volume":"37","author":"Schoffski","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105543","article-title":"BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: A phase I dose-escalation\/expansion multicenter study","volume":"10","author":"Sch\u00f6ffski","year":"2025","journal-title":"ESMO Open."},{"key":"10.1016\/j.critrevonc.2026.105506_bib88","unstructured":"Shanghai Runshi Pharmaceutical Technology Co., Ltd, 2021. A Multi-center, Open-label, Dose Escalation and Expansion, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) Characteristic of SYHA1815 in Subjects With Unresectable Locally Advanced or Metastatic Solid Tumors (Clinical trial registration No. NCT05105464). clinicaltrials.gov."},{"key":"10.1016\/j.critrevonc.2026.105506_bib89","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00428-024-03890-w","article-title":"High success rate of first proficiency testing for RET fusions and RET mutations in lung and thyroid cancer samples by various methods","volume":"485","author":"Siebolts","year":"2024","journal-title":"Virchows Arch."},{"key":"10.1016\/j.critrevonc.2026.105506_bib90","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2020.01.006","article-title":"RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies","volume":"15","author":"Solomon","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib91","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1038\/s41375-022-01660-8","article-title":"Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia","volume":"36","author":"Soverini","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2026.105506_bib92","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","article-title":"Precision Targeted Therapy with BLU-667 for RET -Driven Cancers","volume":"8","author":"Subbiah","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105506_bib93","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1089\/thy.2023.0363","article-title":"Pralsetinib in Patients with Advanced\/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study","volume":"34","author":"Subbiah","year":"2024","journal-title":"Thyroid\u00ae"},{"key":"10.1016\/j.critrevonc.2026.105506_bib94","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diabetes & Endocrinol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib95","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.annonc.2020.10.599","article-title":"Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib96","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.annonc.2021.02.010","article-title":"Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib97","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e15107","article-title":"The development of APS03118, a potent next-generation RET inhibitor for treating RET-inhibitor-resistant patients","volume":"40","author":"Subbiah","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib98","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.annonc.2020.10.002","article-title":"Defining resistance mechanisms to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer","volume":"31","author":"Tan","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib99","unstructured":"Turning Point Therapeutics, Inc, 2024. A Phase 1\/2 Study of TPX-0046, A Novel Oral RET\/SRC Inhibitor in Adult Subjects With Advanced\/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations (Clinical trial registration No. NCT04161391). clinicaltrials.gov."},{"key":"10.1016\/j.critrevonc.2026.105506_bib100","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/ERC-19-0259","article-title":"Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response","volume":"27","author":"Valerio","year":"2020","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105506_bib101","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.2009.23.6604","article-title":"Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"28","author":"Wells","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib102","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib103","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.23.02503","article-title":"Durability of Response With Selpercatinib in Patients With RET -Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001","volume":"42","author":"Wirth","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib104","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of Selpercatinib in RET-Altered Thyroid Cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105506_bib105","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1158\/1078-0432.CCR-20-3208","article-title":"A Performance Comparison of Commonly Used Assays to Detect RET Fusions","volume":"27","author":"Yang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105506_bib106","doi-asserted-by":"crossref","first-page":"djag190","DOI":"10.1093\/jnci\/djag190","article-title":"Association of common genetic alterations with tumor recurrence in papillary thyroid cancer","volume":"12","author":"Yu","year":"2026","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2026.105506_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113826","article-title":"The genomic and evolutionary landscapes of anaplastic thyroid carcinoma","volume":"43","author":"Zeng","year":"2024","journal-title":"Cell. Rep."},{"key":"10.1016\/j.critrevonc.2026.105506_bib108","article-title":"A real-world pharmacovigilance study of Sorafenib based on the FDA Adverse Event Reporting System","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188928","article-title":"Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities","volume":"1878","author":"Zhang","year":"2023","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews Cancer"},{"key":"10.1016\/j.critrevonc.2026.105506_bib110","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1021\/acs.jmedchem.4c02692","article-title":"Discovery of an Efficacious RET PROTAC Degrader with Enhanced Antiproliferative Activity against Resistant Cancer Cells Harboring RET Solvent-Front Mutations","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.critrevonc.2026.105506_bib111","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1186\/s12964-024-01837-x","article-title":"Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives","volume":"22","author":"Zhang","year":"2024","journal-title":"Cell. Commun. Signal."},{"key":"10.1016\/j.critrevonc.2026.105506_bib112","article-title":"A comprehensive overview of the relationship between RET gene and tumor occurrence","volume":"13","author":"Zhao","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib113","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.jtho.2021.03.006","article-title":"Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET\u2013positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib","volume":"16","author":"Zhu","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105506_bib114","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cca.2009.11.028","article-title":"Molecular rearrangements in papillary thyroid carcinomas","volume":"411","author":"Zitzelsberger","year":"2010","journal-title":"Clin. Chim. Acta"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:45:33Z","timestamp":1793943933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":114,"alternative-id":["S1040842826003938"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105506","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RET alterations in thyroid cancer: Molecular mechanisms, targeted therapies, and emerging resistance","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105506","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105506"}}